Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib, Camrelizumab, and Pegaspargase in NK/T-cell Lymphoma
NCT06376721Phase 2Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Apr 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of linperlisib in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Beijing Tongren Hospital. Primary endpoint: Best Objective Response Rate. Started Apr 2024; status: recruiting.
02
Drugs
linperlisib
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT06376721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06376721.